Safety
Boniva (ibandronate sodium) Tablets
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- November 2008
| The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary. Read about the new physician labeling format. |
| Sections Modified |
Summary of Changes to Contraindications and Warnings |
|
WARNINGS & PRECAUTIONS
ADVERSE REACTIONS
DRUG INTERACTIONS
USE IN SPECIFIC POPULATIONS
PATIENT COUNSELING INFORMATION
PATIENT PACKAGE INSERT
|
WARNINGS & PRECAUTIONS Upper Gastrointestinal Adverse Reactions: ...Advise patients to comply with the dosing instructions to minimize the risk of these effects. Discontinue use if new or worsening symptoms develop (see DOSAGE AND ADMINISTRATION [2.2], ADVERSE REACTIONS [6]). Hypocalcemia and Mineral Metabolism: ...Adequate intake of calcium and vitamin D is important in all patients to prevent hypocalcemia (see DOSAGE AND ADMINISTRATION [2.3]). Hypocalcemia following dosing has been reported postmarketing. Musculoskeletal Pain: ...Consider discontinuing use if severe symptoms develop.
|

